TL;DR — Luteolin is a preclinical anti-inflammatory and senotherapeutic candidate; available human work uses small studies or combination formulations. Evidence tierTNiC's A/B/C grading of how strong the human research is behind a compound. Full glossary →: C. Use only when the goal and monitoring plan are clear.
What Luteolin does
Luteolin is a dietary flavone found in celery, parsley, chamomile, and peppers, structurally close to apigenin. Its most-studied action is anti-inflammatory — particularly the ability to calm activated microglia (the brain's immune cells) and stabilize mast cells, which is why the preclinical interest centers on neuroinflammation. It is also examined as a candidate senotherapeutic. The honest limit: the compelling data is largely cell and rodent work, and the human studies are small or use combination formulations — hence the Tier C grade.
Primary hallmarks targeted: Chronic inflammation (NF-κB / cytokine suppression) · Cellular senescence (candidate senotherapeutic)
The strongest evidence is preclinical — luteolin suppresses NF-κB-driven cytokine release and microglial activation in cell and animal models. Human work is limited to small studies or multi-ingredient formulations, so the senescence and neuroinflammation claims remain hypothesis-generating, not proven in people.
Mechanism and biological context
Luteolin's core mechanism is transcriptional: it inhibits NF-κB signaling and downstream pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), and it stabilizes mast cells so they release fewer inflammatory mediators. Because it crosses the blood-brain barrier reasonably well for a flavonoid, much of the interest is in the CNS, where it dampens microglial over-activation implicated in neuroinflammatory aging. It is also a direct antioxidant. Like most flavones, native oral bioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → is modest, so it is often paired with fat or delivered in enhanced-absorption forms.
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| NF-κB inhibition | Suppresses pro-inflammatory gene transcription | Chronic inflammation |
| Mast-cell stabilization | Reduces histamine/cytokine release | Chronic inflammation |
| Microglial modulation | Calms CNS immune activation (crosses BBB) | Altered intercellular communication |
| Senotherapeutic signal | Preclinical activity against senescent cells | Cellular senescence |
The biology is coherent and consistent across models; what is missing is the human trial base to turn "anti-inflammatory in a dish and in mice" into a defined clinical effect.
Evidence summary
| Study | Source | Year | Citation |
|---|---|---|---|
| Progress in the treatment of drug-induced liver injury with natural products. | Pharmacological research | 2022 | PMID 35882295 |
| Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. | Journal of ethnopharmacology | 2018 | PMID 29801717 |
| The favorable impacts of cardamom on related complications of diabetes: A comprehensive literature systematic review. | Diabetes & metabolic syndrome | 2024 | PMID 38325073 |
← Swipe for more columns →
Evidence verdict: Tier C. These records establish that the topic is represented in peer-reviewed literature. Read each design and population before applying its result; adjacent evidence is not interchangeable with a dedicated trial.
Where luteolin disappoints
- It's preclinical. The anti-inflammatory and microglial effects are cell and rodent work; the human studies are small or use multi-ingredient formulations, so no effect is proven in people. - It's largely redundant with apigenin. Luteolin is apigenin plus one hydroxyl, hitting overlapping NF-κB/CD38 pathways — running both is duplicate coverage, not additive. - Flavone bioavailability is poor. Like its cousins, absorption is low without a suitable formulation — a ceiling on whatever the mechanism could deliver.
What would change this grade. Luteolin is C — a solid preclinical anti-inflammatory/senotherapeutic mechanism with no clean human evidence. A trial of isolated luteolin on an inflammatory, neuro, or senescence endpoint would move it; combination-formula results won't.
Is Luteolin a fit?
Is there a defined goal, a plausible deficiency/indication, and a measurable endpoint?
Consider a time-bounded, monitored trial at the evidence-aligned dose.
Defer it; adding compounds without a decision rule increases cost and interaction risk.
Pregnancy, organ disease, anticoagulation, or interacting medication: obtain clinician review first.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Practical standard |
|---|---|
| Dose | 50-100 mg/day |
| Timing | with food |
| Trial length | 8–12 weeks unless the cited indication specifies otherwise |
| Stop rule | Adverse effects, worsening labs, or no meaningful response at review |
A disciplined trial
- Record the exact product, form, and dose.
- Change one major variable at a time.
- Define the endpoint and stop rule before starting.
- Do not extrapolate a disease-population dose to healthy self-experimentation.
Monitoring
| Monitor | When | Why |
|---|---|---|
| Goal-specific symptom or performance metric | Baseline and weekly | Detect a practical response |
| Medication and adverse-effect review | Baseline and each change | Catch interactions early |
| Relevant clinician-selected labs | Baseline and 8–12 weeks | Verify safety and direction |
Question
Vague longevity hope
Review
Indefinite
Question
Specific measurable goal
Review
8–12 week decision point
Safety and red flags
Do not confuse availability with safety
Stop for allergy, persistent gastrointestinal symptoms, neurologic changes, jaundice, unusual bleeding, or any clinically important deterioration.
Evidence in one population does not establish safety in pregnancy, organ impairment, or polypharmacy. Product quality and dose accuracy matter.
Who should skip luteolin
- Anyone already taking apigenin — near-identical flavone, redundant coverage; don't pay for both. - Anyone expecting a proven effect — the human evidence is small or combination-based, not isolated-luteolin outcomes. - Anticoagulant users and pregnancy/nursing — flavone antiplatelet potential and absent safety data; get clearance.
Synergies and antagonists
Pairs well with:
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Apigenin | Near-identical flavone hitting overlapping NF-κB/CD38 pathways | Treat as redundant — pick one, not both |
| Anticoagulants / antiplatelets | Flavones carry a mild antiplatelet potential | Physician review before combining |
| Taking it fat-free | Poor flavone absorption without dietary fat/formulation | Dose with a fat-containing meal |
Start with the smallest stack that answers the question. SynergyWhen two compounds together produce greater effect than either alone. Full glossary → is a mechanistic hypothesis unless a combination trial demonstrates it.
Personal results template
My Luteolin results log
| Date | Dose / timing | Primary endpoint | Safety notes | Decision |
|---|---|---|---|---|
| YYYY-MM-DD | Baseline | — | — | Start / defer |
| YYYY-MM-DD | Week 4 | — | — | Continue / adjust / stop |
| YYYY-MM-DD | Week 12 | — | — | Keep / stop |
← Swipe for more columns →
Success rule: a meaningful, repeatable improvement in the preselected endpoint without unacceptable adverse effects or lab movement.
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.